PMC full text:
Published online 2024 Mar 13. doi: 10.1136/bmjresp-2023-002161
Table 1
Evaluation of the selected publications according to the GRADE methodology
| Vasoactive drug | Study | GRADE |
| Riociguat | Nathan et al 19 | Moderate |
| Sildenafil | Jackson et al 23 | Very low |
| Behr et al 24 | Moderate | |
| Tadalafil | No study identified | – |
| Bosentan | Corte et al 25 | Low |
| Baughman et al 26 | Very low | |
| Macitentan | No study identified | – |
| Ambrisentan | Raghu et al 27 | Very low |
| Raghu et al 28 | Very low | |
| NCT00879229 | Very Low | |
| Treprostinil | Waxman et al 20 | Moderate |
| Nathan et al 29 | Low | |
| Nathan et al 30 | Low | |
| Iloprost | No study identified | – |
| Selexipag | No study identified | – |
| Isosorbide | No study identified | – |
GRADE, Grades of Recommendation, Assessment, Development, and Evaluation.